Jupiter Neurosciences, Inc.

Company focus

• Clinical-stage research and development company focused on neuroinflammation and CNS disorders using a resveratrol-based platform.
• Primary platform: JOTROL™, an enhanced oral formulation of resveratrol designed to improve bioavailability.
• Two operating segments:
  • Nugevia: premium consumer nutraceutical line (longevity and wellness).
  • Pharmaceutical operations: development of drug candidates based on JOTROL™ for CNS and rare diseases.

What the company does

• Develops and advances drug candidates built on the JOTROL™ micellar resveratrol platform, with a current top priority on Parkinson’s disease (JNS115, Phase IIa).
• Maintains a consumer health and wellness business under the Nugevia brand; launched March 2025 with DTC sales beginning in Q4 2025.
• Pursues collaborations and out-licensing opportunities, particularly in Asia, with milestone, royalty, and equity-based arrangements.
• Holds an exclusive worldwide license from Aquanova for JOTROL™ technology, including related IP and manufacturing know-how (NovaSOL® micellar delivery).

Product pipeline and development

JOTROL™ platform

• Core product: micellar resveratrol formulation delivered in softgels (100 mg per capsule).
• Exclusive global license with Aquanova; co-owned patent family with expiry in 2036 and filings/grants covering the US, Japan, China, Hong Kong, and parts of Europe.
• Licensing terms: worldwide exclusivity; $20,000 upfront; $75,000 annual license fee; $200,000 milestone per territory upon regulatory approval; 5% royalties on net sales; option to reduce royalties to 1.25% in exchange for a $3 million one-time payment under specified agreement terms.

Pipeline indications and status

• JNS115 — Parkinson’s Disease (PD): Phase IIa IND finalized by FDA Nov 2025; first dosing expected Q2 2026; multicenter US trial with ~30 participants across three centers; primary goals include metabolic and biomarker endpoints; topline results anticipated ~12 months after first dosing.
• JNS108 — Mild Cognitive Impairment / early Alzheimer’s Disease (MCI/early AD): prior Phase II work and NIH/NIA grant activity; Phase II planning contingent on PD program results and additional grant support.
• JNS102 — MPS I and JNS107 — MELAS: proposed Phase II studies targeting rare diseases with potential CNS involvement.

Other development notes

• Cross-referencing of prior Phase I resveratrol data with future trials requires FDA approval; current cross-reference use is applied to the Parkinson’s Phase IIa study.

Nugevia brand (consumer wellness)

• Launch and products:
  • Nugevia GLO: supports skin vitality and cellular functions.
  • Nugevia MND: supports cognitive resilience and mental clarity.
  • Nugevia PWR: supports mitochondrial function and energy.
• Availability and channel:
  • Ships in the US with planned international market expansion.
  • Initial product formulations and DTC sales began in Q4 2025 via the Nugevia website.
• Marketing and partnerships:
  • Brand ambassadors include Annika Sörenstam and Chris Webber.
  • Manufacturing uses Aquanova (NovaSOL® Astaxanthin) with US encapsulation and fulfillment; supply chain includes multiple suppliers and a final fulfillment center in the US.
  • Southeast Asia expansion through service agreements with Longevity Technology Group Limited, Regis Healthcare Group Limited, and Optimize Wellness Limited; strategic partner Dominant Treasure Health Company Limited for China and Southeast Asia.
• Regulatory environment:
  • Nugevia products are dietary supplements subject to DSHEA, cGMP, and related labeling/health-claim limitations in the US and comparable frameworks abroad (e.g., EFSA in the EU); international markets have varying regulatory requirements such as EU Novel Food and regional restrictions.

Intellectual property and licensing

• Key IP: worldwide exclusive license with Aquanova for the JOTROL™ micellar formulation technology; joint ownership of a patent family covering resveratrol solubilization for pharmaceutical use.
• Patent protection: filings and grants in multiple jurisdictions with patent family expiry in 2036.
• The company augments patent coverage with trade secrets and confidential information.
• Trademark activity: intent-to-use filings for JOTROL™ and Nugevia in the US; ongoing brand protection efforts.

Manufacturing and collaborators

• Primary clinical trial manufacturing: Catalent (clinical supplies and production of active and placebo batches for the PD study).
• Primary drug-delivery platform provider: Aquanova (NovaSOL® micellar technology) under exclusive license for JOTROL™.
• Asian development service providers: Optimize Wellness Limited, Regis Healthcare Group Limited, Longevity Technology Group Limited (service agreements with stock-based pre-payments).

Financial snapshot (as of year-end 2025)

• Revenue:
  • 2025: $21,796
  • 2024: $0
• Net loss:
  • 2025: $(8,644,897)
  • 2024: $(2,439,625)
• Cash and liquidity:
  • Cash and cash equivalents as of December 31, 2025: $3,789,342
• Accumulated deficit:
  • As of December 31, 2025: $(34,667,026)
  • As of December 31, 2024: $(26,022,129)
• Financing and capital structure:
  • December 2024 public offering: gross proceeds of $11 million (2,750,000 shares at $4.00 per share); common stock began trading on Nasdaq as JUNS.
  • Standby Equity Purchase Agreement with Yorkville: up to $20 million of potential equity financing, including convertible notes; actual draws depend on market conditions.
• Use of proceeds: funds intended for Phase II efforts in JOTROL™ (PD), Southeast Asia development activities, manufacturing for clinical supplies, and general R&D, working capital, and corporate purposes.

Personnel

• As of December 31, 2025:
  • 5 full-time employees
  • 2 full-time consultants
  • 3 part-time consultants
  • 6 Scientific Advisory Board members
  • Core R&D and operations personnel: 10 (excluding SAB)

Upcoming milestones

• JNS115 PD Phase IIa trial: first dosing planned in Q2 2026; topline results anticipated ~12 months after first dosing.
• Continued development and potential expansion of JOTROL™ into MCI/early AD and other indications, subject to regulatory feedback and funding.
• Nugevia product scaling and international expansion, with ongoing marketing, regulatory compliance, and supply-chain management.

Summary

Jupiter Neurosciences is a small, early-stage biopharma and consumer health company using the JOTROL™ resveratrol delivery platform to pursue CNS and rare-disease drug development, with Parkinson’s disease as the current priority, while operating a consumer wellness business under the Nugevia brand. The company operates with a lean staff, relies on partner manufacturing and Asian development agreements, and has modest current revenue from the Nugevia line alongside ongoing operating losses and a material accumulated deficit. Funding sources include a December 2024 public offering and a Yorkville SEPA facility, with future progress tied to clinical development, partnerships, and regulatory outcomes.